{
    "organizations": [],
    "uuid": "7096f469001cad6ae2dec137c4837ab159603aed",
    "author": "",
    "url": "https://www.reuters.com/article/idUSL8N1Q9138",
    "ord_in_thread": 0,
    "title": "BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 19 (Reuters) - MORPHOSYS AG:\n* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT\n* IN THE STUDY, MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS(AD)PATIENTS\n* 83% OF PATIENTS (5 OUT OF 6) AT THE HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER THE ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4\n* POOLED DATA ACROSS ALL DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106\n* PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018\nSource text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-19T10:04:00.000+02:00",
    "crawled": "2018-02-19T10:27:48.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "morphosys",
        "ag",
        "said",
        "saturday",
        "morphosys",
        "galapagos",
        "present",
        "result",
        "phase",
        "study",
        "mor106",
        "atopic",
        "dermatitis",
        "abstract",
        "study",
        "mor106",
        "generally",
        "well",
        "tolerated",
        "atopic",
        "dermatitis",
        "ad",
        "patient",
        "patient",
        "highest",
        "dose",
        "reached",
        "least",
        "improvement",
        "per",
        "atopic",
        "dermatitis",
        "area",
        "severity",
        "index",
        "week",
        "pooled",
        "data",
        "across",
        "dose",
        "cohort",
        "showed",
        "improvement",
        "ad",
        "symptom",
        "week",
        "compared",
        "baseline",
        "patient",
        "treated",
        "mor106",
        "phase",
        "development",
        "mor106",
        "planned",
        "initiated",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}